1. Introduction {#sec1}
===============

Prostate cancer (PCa) is a major cancer bothering men worldwide. With an estimated 19% new cancer incidence in men, PCa continues to hold the highest morbidity among all cancer types in the United States \[[@B1]\]. During the past decades, urologists have made great progress in the diagnosis and treatment of PCa \[[@B2]\]. Currently, the new types of biomarkers such as liquid biopsy and imaging biomarker start to make contributions to clinical decision making \[[@B3]--[@B5]\]. However, PCa is a heterogeneous cancer with individual disparity; therefore, genomic and molecular resources still play an important role in discriminating aggressive cases and aiding prognosis prediction \[[@B6]\].

MicroRNA (miRNA), also known as short noncoding RNA, is a group of single-stranded RNA molecules that act as posttranscriptional gene regulation \[[@B7]\]. MiRNAs are involved in many cellular biological processes such as proliferation, migration, apoptosis, invasion, and epithelial-mesenchymal transition (EMT). Accumulating evidence shows that miRNAs can functionally act as oncogene or tumor suppressors \[[@B8]\]. In addition, circulating miRNA can be detected without invasion like biopsy \[[@B9]\]. Hence, miRNAs can be applied to help diagnosis and prognosis. Multiple studies of miRNA-PCa have been performed, but they often had the disadvantages of heterogeneous design, small sample size, and less clinical information.

To the best of our knowledge, there are few studies integrating microarray datasets to access key molecules and investigate miRNA-mRNA regulatory networks. The objective of this study is to find the key miRNAs and their potential regulatory mechanisms in PCa by bioinformatic approaches.

2. Materials and Methods {#sec2}
========================

2.1. Microarray Data {#sec2.1}
--------------------

Three gene expression profiles (GSE55945, GSE60329, and GSE103512) and four miRNA expression profiles (GSE26367, GSE64333, GSE21036, and GSE54516) were obtained from the Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo>). The profiles based on PCa cell lines or xenograft models were excluded; thus, only PCa patients and healthy controls were preserved in this study. Every included dataset contains more than ten PCa samples and normal prostate tissues. The characteristics of these profiles are shown in [Table 1](#tab1){ref-type="table"}.

2.2. Data Processing {#sec2.2}
--------------------

We performed the comparison on the two groups of samples (PCa versus normal prostate tissues) in each GEO dataset to identify differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs). The comparison was launched by a limma R package based online program, GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>). The adjusted *P* value (adj. *P* value) from the Benjamini--Hochberg method could correct the false positive results. So we chose the "adj. *P* value\<0.05" and "\|logFC\|\>1" as a primary cut-off criteria to interpret the results. Among the DEMs from the four datasets, only those appeared in two or more datasets were considered as the significant DEMs.

2.3. Identification of miRNA Targets {#sec2.3}
------------------------------------

The MiRWalk 2.0 database provides a large collection of predicted and experimentally verified miRNAs-targets binding sites information \[[@B10]\]. We downloaded the significant DEMs-mRNA intersection data from the MiRWalk 2.0-validated-target miRNA-gene retrieval system, which contains all literature-reported miRNA-target genes. However, the validated target genes were from various diseases models, so the expression of those genes in PCa might not be consistent with other diseases. We subsequently selected the genes from the intersection between the significant DEMs-mRNA intersection data and the DEGs from the three GEO datasets. These genes were defined as the significant DEGs.

2.4. Functional Enrichment Analysis {#sec2.4}
-----------------------------------

The Database for Annotation, Visualization, and Integrated Discovery (DAVID) is an online program that offers functional annotation of enormous quantity of genes derived from various genomic resources \[[@B11]\]. We used the DAVID database to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis on significant DEGs. The species was limited to*Homo sapiens* and the "*P* value \<0.05" was considered statistically significant.

2.5. Interaction and Regulatory Network Establishment {#sec2.5}
-----------------------------------------------------

Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) was used to construct protein-protein interaction (PPI) network. The STRING database collects and predicts interaction information from genomic context predictions, high-throughput lab experiments, coexpression, automated text-mining, and previous knowledge in databases \[[@B12]\]. To access more objective and reliable results, we restricted the sources as high-throughput lab experiments and previous knowledge in databases. In addition, the minimum interaction score was set at high confidence (0.700).

The miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/>) is a miRNA intersection database based on validation from experiments such as assay, microarray, sequencing quantitative PCR, and western blot. The miRanda algorithm from the "microRNA.org-Targets and Expression" was freely available and can be applied to the whole genome sequences using identified miRNA sequences \[[@B13]\]. The two programs above were used to predict target mRNAs of the significant DEMs. When two miRNAs shared a common target mRNA; they might exist in a similar regulatory pathway. The miRNA-mRNA regulatory network was visualized by Cytoscape 3.6.0 \[[@B14]\].

2.6. Validation and Survival Analysis {#sec2.6}
-------------------------------------

The Cancer Genome Atlas (TCGA) database provides abundant clinical information from huge sample size. Therefore, the dataset "TCGA-PRAD" was used to find if the significant DEMs were correlated with survival outcome. The dataset "TCGA-PRAD" consists of 498 PCa samples with 52 normal prostate samples. Among the 494 clinical outcome events available, 484 patients were living and 10 were dead when the follow-up ended. We examined the significant DEMs expression, relationship with PCa stages, and survival. The "t-test" was applied to check expression level, while the chi-square test was used on different stages. The Kaplan-Meier plots were constructed by OncomiR \[[@B15]\]. The "*P*value \<0.05" was considered statistically significant.

3. Results {#sec3}
==========

3.1. DEGs/DEMs Identification {#sec3.1}
-----------------------------

After being compared with normal prostate tissues, the results of GEO2R analysis showed that there were totally 2333 upregulated DEGs ([Figure 1(b)](#fig1){ref-type="fig"}), 1188 downregulated DEGs ([Figure 1(c)](#fig1){ref-type="fig"}), and 193 DEMs ([Figure 1(a)](#fig1){ref-type="fig"}) in PCa samples. Among them, 26 DEMs appeared in the results of two datasets at least, so they were identified as significant DEMs. Additionally, miR-183 was the only DEM in all four datasets simultaneously. The following DEMs were found in three datasets: miR-96, miR-375, miR-143, miR-1, and miR-145.

By MiRWalk 2.0-validated-target miRNA-gene retrieval system, we got 4475 candidate genes of the 26 significant DEMs. The intersection number of these candidate genes and the upregulated DEGs was 633. For the downregulated DEGs, 261 genes were intersected with the 4475 candidate genes. Therefore, the 633 upregulated and the 261 downregulated genes were identified as the final sets of significant DEGs.

3.2. GO and Pathway Enrichment {#sec3.2}
------------------------------

The GO ontology contains three terms: cellular component (CC), molecular function (MF), and biological process (BP). The results demonstrated that the most significant GO terms for upregulated significant DEGs were "protein binding (MF)", "nucleoplasm (CC)", and "poly(A) RNA binding (MF)", whereas for the downregulated significant DEGs, "extracellular matrix (CC)", "cell surface (CC)", and "protein binding (MF)" turned to be important ([Table 2](#tab2){ref-type="table"}).

Furthermore, the KEGG pathway analysis indicated that "prostate cancer", "TGF-beta signaling pathway", "TNF signaling pathway", and "focal adhesion" pathways played an essential role in PCa pathogenesis ([Table 2](#tab2){ref-type="table"}).

3.3. PPI Network {#sec3.3}
----------------

PPI networks were established separately by significant upregulated DEGs ([Figure 2(a)](#fig2){ref-type="fig"}) and significant downregulated DEGs ([Figure 2(b)](#fig2){ref-type="fig"}). In respect of the former, 294 nodes and 926 edges in total constituted the PPI network. In regard to the latter, the network was composed of 93 nodes and 153 edges.

In a PPI network, the more edges a gene has, the more important role it plays (like a seed). We used the parameter "degree" to calculate edge counts of every single gene in a PPI network. The top 5% degree genes were listed in [Table 3](#tab3){ref-type="table"}, which were assessed as hub genes.

3.4. MiRNA-mRNA Regulatory Network {#sec3.4}
----------------------------------

As demonstrated in [Figure 3](#fig3){ref-type="fig"}, the target genes were predicted by miRanda and miRTarbase, among which two or more miRNA might target the same mRNA. For instance, miR-1, miR-145, miR-143, miR-205, and miR-31 all had interactions with cyclin dependent kinase 4 (CDK4). There were 21 mRNA nodes which might interact with more than two miRNAs.

3.5. Validation and Kaplan-Meier Curves {#sec3.5}
---------------------------------------

After comparing the expression level of miRNAs in the TCGA dataset, we found that 23 among the 26 significant DEMs were in accordance with the results in GEO databases. However, the expression of miR-1, miR-519b, and miR-572 was not significantly different between PCa samples and normal control prostate tissues. The relationship of miRNAs between the clinical TNM stages was also tested in the TCGA dataset using chi-square analysis. The results of the significant DEMs were shown in [Table 4](#tab4){ref-type="table"}.

We subsequently drew Kaplan-Meier plots ([Figure 4](#fig4){ref-type="fig"}) based on the TCGA survival data. Four significant DEMs, miR-95, miR-23b, miR-143, and miR-183 were found related to overall survival (OS) in PCa patients. The higher expression of these miRNAs meant poor OS in patients with PCa.

4. Discussion {#sec4}
=============

In the present study, we identified 26 significant DEMs, 633 upregulated DEGs, and 261 downregulated DEGs. The results of functional enrichment analysis indicated that the significant DEGs were related to TGF-beta signaling pathway and TNF signaling pathway in PCa. The key DEGs such as HSPA8, PPP2R1A, CTNNB1, ADCY5, ANXA1, and COL9A2 were found as hub genes in PPI networks. Importantly, some of the DEMs were validated and found correlated with tumor stages and survival, which meant the miRNAs could not only regulate cellular process but also be of high value in clinical practice.

In fact, prostate cancer shares a plenty of pathways with other cancers such as TNF, TGF-beta pathways. Some unique signal pathways like the androgen receptor (AR) and transmembrane protease serine 2 (TMPRSS2) relevant pathways also play a crucial role in PCa. In these complicated processes, miRNAs nearly take part in all key cellular pathways considering that one miRNA can interact with many mRNAs and one mRNA can also interact with many miRNAs. Interestingly, miR-183 was the only one significant DEM expressed in all four different datasets. We assumed that ethnics and sample size may cause this heterogeneity. In accordance with our result, miR-183 has been testified overexpression in PCa serum, tissue, and cell line \[[@B16]\]. Ueno reported that miR-183 could target Dkk-3 and SAMAD4 and has an oncogenic biological behavior \[[@B17]\]. Due to the paralogous property of miR-183, miR-96, and miR-182, these three miRNAs have been studied as miR-183 cluster, which could regulate zinc levels and carcinogenic pathways in prostate cells \[[@B18]\]. MiR-96 was also reported enhancing PCa cell proliferation through FOXO1 \[[@B19]\], which could be speculated in the PPI network ([Figure 2(a)](#fig2){ref-type="fig"}). Except for the previously reported miRNAs, there are also some miRNAs not reported in PCa before like miR-95. We found that higher miR-95 expression indicated poor survival based on 494 patients in TCGA. However, we do not know if miR-95 is related to the survival of patients from other regions or countries. The mechanisms and in-depth pathways of miR-95 should also be investigated by experiments in the future.

By constructing the PPI network, we can recognize the key genes that miRNAs may interact with. Since the genes were filtered by the 26 significant DEMs potential targets, there were still 633 upregulated and 261 downregulated. Therefore, when it comes to all the 197 DEMs, the enormous and complicated miRNA-mRNA regulatory network can be imaginable. The hub genes of a network are always important like "seeds", which connect different signal pathways. In the present study, we identified several hub genes. The regulating mechanisms HSPA8 were reported in malignancies like glioblastoma and myeloid leukaemia \[[@B20], [@B21]\]. The PPP2R1A mutation in uterine cancer was reported acting through a dominant-negative mechanism to promote cancer cell growth \[[@B22]\]. Besides, emerging evidence points out that the histone cluster is contributed to various kinds of cancers \[[@B23]\]. As a phospholipid-dependent, membrane-binding protein, the ANXA1 upregulation can enhance drug-resistance of PCa therapy \[[@B24]\]. In our predicted miRNA-mRNA network, the key mRNAs like CDKN1A,B,C and CDK4 are cell-cycle related modulators \[[@B25]\]. To sum up, the miRNA regulatory network may provide potential targets for new drug development and treatment. By exploiting the bioinformatic analysis on miRNAs and regulatory pathways, we can discover important and novel potential targets in the tumor-genesis, diagnosis, prognosis, and key mechanisms in different cancers such as lung cancer \[[@B26]\], gastric cancer \[[@B27]\], colorectal cancer \[[@B28]\], and thyroid cancer \[[@B29]\].

Although this study firstly investigated miRNAs\' regulatory role in PCa by integrating multiple microarray datasets, we still need to clarify some limitations. Firstly, the stages and aggressiveness of PCa were not restricted. We only researched the PCa versus normal prostate. Key miRNAs and genes in different periods like metastatic castration-resistant PCa call for deeper exploration. Secondly, the source of microarray is only tissues. Body fluid like serum, urine, and prostatic fluid may contain circulating miRNAs, which are more likely to be accepted for clinical application. Thirdly, though we validated our results in TCGA data, the microarray results were not validated by experiments like qRT-PCR, functional experiments in vitro. Further studies are needed to validate our results by experiments on large samples.

5. Conclusions {#sec5}
==============

We identified 26 miRNAs that may take part in key pathways like TGF-beta, TNF pathways in prostate cancer regulatory networks. MicroRNAs like miR-23b, miR-95, miR-143, and miR-183 can be utilized in assisting the diagnosis and prognosis of prostate cancer as biomarkers. Further experimental studies are required to validate our results.
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###### 

Characteristics of the microarray datasets from GEO database.

  Accession/ID   PMID       Platform   Number of prostate cancer tissues   Number of normal prostate tissues (control)   Gene/microRNA
  -------------- ---------- ---------- ----------------------------------- --------------------------------------------- ---------------
  GSE26367       24713434   GPL11350   n=173                               n=11                                          microRNA
  GSE64333       26089375   GPL8227    n=27                                n=27                                          microRNA
  GSE21036       20579941   GPL8227    n=113                               n=28                                          microRNA
  GSE54516       25485837   GPL18234   n=51                                n=48                                          microRNA
  GSE55945       19737960   GPL570     n=13                                n=8                                           Gene
  GSE60329       27384993   GPL14450   n=54                                n=14                                          Gene
  GSE103512      29133367   GPL13158   n=60                                n=7                                           Gene

###### 

Results of top 10 gene ontology (GO) categories and the top 5 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.

  Category                  Term   Description                                                            Gene counts   *P*-value
  ------------------------- ------ ---------------------------------------------------------------------- ------------- -----------
  **Up-regulated gene**                                                                                                  
   GO:0005515               MF     protein binding                                                        416           1.40E-20
   GO:0005654               CC     nucleoplasm                                                            164           5.20E-14
   GO:0044822               MF     poly(A) RNA binding                                                    88            1.80E-12
   GO:0005829               CC     cytosol                                                                180           3.00E-12
   GO:0005913               CC     cell-cell adherens junction                                            40            3.20E-12
   GO:0098641               MF     cadherin binding involved in cell-cell adhesion                        37            4.00E-11
   GO:0070062               CC     extracellular exosome                                                  153           2.50E-10
   GO:0005634               CC     nucleus                                                                252           3.10E-10
   GO:0098609               BP     cell-cell adhesion                                                     33            1.40E-09
   GO:0005737               CC     cytoplasm                                                              237           1.90E-08
   hsa05215                 KEGG   Prostate cancer                                                        14            4.10E-05
   hsa04350                 KEGG   TGF-beta signaling pathway                                             11            1.80E-03
   hsa05202                 KEGG   Transcriptional misregulation in cancer                                16            2.80E-03
   hsa05210                 KEGG   Colorectal cancer                                                      9             3.00E-03
   hsa04910                 KEGG   Insulin signaling pathway                                              14            3.30E-03
  **Down-regulated gene**                                                                                                
   GO:0031012               CC     extracellular matrix                                                   23            2.20E-10
   GO:0009986               CC     cell surface                                                           28            1.30E-08
   GO:0005515               MF     protein binding                                                        170           1.00E-07
   GO:0005925               CC     focal adhesion                                                         22            1.70E-07
   GO:0030198               BP     extracellular matrix organization                                      16            2.30E-07
   GO:0005578               CC     proteinaceous extracellular matrix                                     17            1.30E-06
   GO:0007155               BP     cell adhesion                                                          22            4.80E-06
   GO:0045944               BP     positive regulation of transcription from RNA polymerase II promoter   34            8.30E-06
   GO:0008201               MF     heparin binding                                                        12            2.40E-05
   GO:0030574               BP     collagen catabolic process                                             8             4.30E-05
   hsa04668                 KEGG   TNF signaling pathway                                                  12            3.30E-06
   hsa04510                 KEGG   Focal adhesion                                                         16            4.80E-06
   hsa05205                 KEGG   Proteoglycans in cancer                                                15            1.60E-05
   hsa05144                 KEGG   Malaria                                                                7             2.50E-04
   hsa04064                 KEGG   NF-kappa B signaling pathway                                           8             1.00E-03

BP: biological process; CC: cellular component; MF: molecular function

###### 

The top 5% hub genes in the protein-protein interaction (PPI) networks.

  Entrez Gene ID            Gene symbol   Full gene name                                           Degree
  ------------------------- ------------- -------------------------------------------------------- --------
  **Up-regulated gene**                                                                             
   3312                     HSPA8         heat shock protein family A (Hsp70) member 8             40
   5518                     PPP2R1A       protein phosphatase 2 scaffold subunit Aalpha            32
   1499                     CTNNB1        catenin beta 1                                           25
   8334                     HIST1H2AC     histone cluster 1 H2A family member c                    24
   10921                    RNPS1         RNA binding protein with serine rich domain 1            23
   85236                    HIST1H2BK     histone cluster 1 H2B family member k                    22
   8970                     HIST1H2BJ     histone cluster 1 H2B family member j                    22
   5878                     RAB5C         RAB5C, member RAS oncogene family                        22
   595                      CCND1         cyclin D1                                                21
   8301                     PICALM        phosphatidylinositol binding clathrin assembly protein   21
   25977                    NECAP1        NECAP endocytosis associated 1                           21
   51429                    SNX9          sorting nexin 9                                          21
   8349                     HIST2H2BE     histone cluster 2 H2B family member e                    20
   1026                     CDKN1A        cyclin dependent kinase inhibitor 1A                     20
  **Down-regulated gene**                                                                           
   111                      ADCY5         adenylate cyclase 5                                      12
   301                      ANXA1         annexin A1                                               11
   1298                     COL9A2        collagen type IX alpha 2 chain                           10
   1277                     COL1A1        collagen type I alpha 1 chain                            9

###### 

Results of the significant DEMs expression validation and the relationship with PCa clinical stages in TCGA data.

  ----------------------------------------------------------------------------------------------------------
  MiRNA ID          Up-regulated in   *P*-value (t-test)   Clinical stages          *P*-value (chi-square)
  ----------------- ----------------- -------------------- ------------------------ ------------------------
  hsa-miR-133a-3p   normal            8.93E-03             pathologic T/ N status   9.50e-09/ 1.32e-04

  hsa-miR-133b      normal            9.53E-07             pathologic T/ N status   7.96e-07/ 8.83e-05

  hsa-miR-143-3p    normal            1.10E-13             clinical T/ M status     5.04e-03/3.70e-03

  hsa-miR-145-3p    normal            1.65E-07             pathologic T/ N status   7.86e-07/ 1.49e-04

  hsa-miR-148a-3p   tumor             7.67E-13             \-                       \-

  hsa-miR-148a-5p   tumor             4.66E-10             pathologic T status      2.10e-03

  hsa-miR-153-3p    tumor             4.12E-20             pathologic T status      4.30e-02

  hsa-miR-182-5p    tumor             7.57E-16             clinical T/ M status     4.23e-03/ 3.06e-02

  hsa-miR-183-5p    tumor             1.56E-15             pathologic T status/\    7.85e-03/ 1.25e-03
                                                           Clinical M Status        

  hsa-miR-187-3p    normal            1.52E-10             \-                       \-

  hsa-miR-204-5p    normal            2.62E-06             pathologic T/ N status   2.44e-03/ 1.77e-02

  hsa-miR-205-5p    normal            1.39E-02             pathologic T status      1.17e-02

  hsa-miR-221-3p    normal            6.18E-10             pathologic T/ N status   4.10e-07/ 3.70e-04

  hsa-miR-221-5p    normal            1.44E-05             pathologic T/ N status   5.69e-03/ 5.19e-03

  hsa-miR-222-3p    normal            5.76E-07             pathologic T/ N status   4.71e-09/ 2.77e-04

  hsa-miR-222-5p    normal            1.17E-04             pathologic T status/\    1.37e-03/ 4.81e-02
                                                           Clinical M Status        

  hsa-miR-224-5p    normal            2.31E-02             pathologic T status      5.62e-04

  hsa-miR-23b-3p    normal            8.14E-03             pathologic T/ N status   9.60e-03/ 3.24e-02

  hsa-miR-31-3p     normal            3.97E-02             \-                       \-

  hsa-miR-32-3p     tumor             2.96E-03             pathologic T/ N status   3.29e-03/ 3.81e-02

  hsa-miR-363-3p    tumor             1.18E-08             pathologic N status      2.92e-02

  hsa-miR-375       tumor             8.87E-13             \-                       \-

  hsa-miR-550a-5p   tumor             1.08E-04             \-                       \-

  hsa-miR-7-5p      tumor             1.70E-03             pathologic T/ N status   4.28e-02/ 2.03e-03

  hsa-miR-95-3p     tumor             8.29E-06             pathologic T status      7.17e-03

  hsa-miR-96-5p     tumor             1.65E-15             pathologic N status/\    4.72e-02/ 5.81e-03
                                                           Clinical M Status        
  ----------------------------------------------------------------------------------------------------------
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